Meitheal Pharmaceuticals Announces FDA Approval of Garzulys™ (insulin aspart-fsan), a Biosimilar to NovoLog
核心洞察
The FDA has approved Garzulys™ (insulin aspart-fsan (搜索)), a rapid-acting human insulin analog biosimilar to NovoLog®, for glycemic control in adults and pediatric patients with diabetes mellitus (搜索).
Meitheal Pharmaceuticals (搜索) served as the U.S. Regulatory Agent and holds exclusive U.S. commercialization rights under a license agreement with Emerge Bioscience (搜索), the BLA holder.
The approval represents a milestone in Meitheal's strategic expansion from generic injectables into complex biologics and branded products.
The U.S. Food and Drug Administration has approved Garzulys™ (insulin aspart-fsan (搜索)) injection, a rapid-acting human insulin analog and biosimilar to NovoLog® (insulin aspart), for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus (搜索). The approval, announced by Chicago-based Meitheal Pharmaceuticals (搜索), Inc., marks a significant step in the company's ongoing expansion beyond its established generic injectable business into the biologics and branded products arena.
Garzulys formulations are approved for both subcutaneous and intravenous administration. Emerge Bioscience (搜索) Pte. Ltd., a Singapore-based subsidiary of Nanjing King-Friend Biochemical Pharmaceutical (搜索) Co., Ltd. (NKF), is the holder of the approved Biologics License Application (BLA). Meitheal served as the product's U.S. Regulatory Agent and holds exclusive U.S. commercialization rights under its license agreement with Emerge.
A Multi-Company Global Collaboration
The development of Garzulys reflects a complex, cross-border partnership involving several biopharmaceutical organizations. Tonghua Dongbao Pharmaceutical (搜索) Co., Ltd., a China-based company specializing in diabetes and metabolic disease therapies, was responsible for drug substance development. NKF handled drug product development, while Xentria, Inc., headquartered in Chicago, led the clinical development program. Meitheal, serving as the U.S. Regulatory Agent, spearheaded the U.S. regulatory work that supported the FDA approval.
The collaboration, initiated in 2023 between Tonghua Dongbao and NKF, encompasses Garzulys as well as two additional insulin biosimilar candidates currently in development. Through its exclusive license agreement with Emerge, Meitheal holds U.S. commercialization rights for all three products.
"The FDA approval of Garzulys represents an important milestone in Meitheal's continued expansion beyond our established generic injectable business and into a broader portfolio of biologics and branded products," said Tom Shea, Chief Executive Officer of Meitheal. "We are making deliberate, long-term investments in the regulatory expertise, commercial infrastructure and strategic partnerships needed to expand patient access to high-quality biologic treatment options."
Strategic Significance for Meitheal
Since its founding in 2017, Meitheal has developed a diversified U.S. platform supporting more than 80 FDA-approved products across therapeutic areas including anti-infectives, oncology, anesthesia, diabetes, critical care, and fertility. The Garzulys approval further expands the company's presence in diabetes care and advances its strategy to build a broader portfolio of biologics and branded products.
Safety and Clinical Considerations
As a biosimilar to NovoLog, Garzulys carries the same safety profile and warnings associated with insulin aspart products. Hypoglycemia is the most common adverse effect, and severe hypoglycemia can cause seizures, lead to unconsciousness, and may be life-threatening or cause death. The product is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Garzulys or its excipients.
Key warnings and precautions include the risk of hyperglycemia or hypoglycemia with changes in insulin regimen, hypersensitivity reactions including anaphylaxis, hypokalemia, and fluid retention with concomitant use of PPAR-gamma agonists such as thiazolidinediones. Patients using insulin pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure. Adverse reactions observed with Garzulys include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus.
The prescribing information emphasizes that Garzulys prefilled pens must never be shared between patients, even if the needle is changed, due to the risk of blood-borne pathogen transmission.
About the Partner Organizations
Tonghua Dongbao, founded in 1985 and based in Jilin Province, China, developed China's first domestically produced recombinant human insulin in 1998 and maintains a portfolio spanning human insulin, insulin analogs, and GLP-1 receptor agonists. NKF, founded in 1986 and headquartered in Nanjing, China, is an integrated biopharmaceutical company with established expertise in heparin APIs and sterile injectable products. Xentria, established in 2020 and based in Chicago, focuses on advancing challenging drug development through innovative collaborations. Emerge Bioscience (搜索), established in 2024, coordinates international pharmaceutical trading and supply-chain activities to support NKF's global growth strategy.